BRCA gene mutations in cancer
Research Guide

Miki et al. (1994) identified a strong candidate for the 17q-linked BRCA1 gene through positional cloning, detecting probable predisposing mutations in five of eight kindreds with breast and ovarian cancer. These mutations impair DNA repair, elevating cancer risk. The discovery enabled subsequent genetic testing for carriers.

Richards et al. (2015) provide joint consensus recommendations from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology for classifying sequence variants. Categories include pathogenic, likely pathogenic, uncertain significance, likely benign, and benign based on population data, computational predictions, and functional studies. These standards guide genetic counseling and patient management.

Lichtenstein et al. (2000) studied twins from Sweden, Denmark, and Finland, finding inherited factors make a minor contribution to most neoplasms. Heritability is higher for specific sites like breast cancer, indicating environmental factors dominate sporadic cases. This highlights gaps in understanding familial cancer genetics.

Davey Smith and Hemani (2014) describe Mendelian randomization as using genetic variants as instrumental variables to infer causality in epidemiological studies. It addresses confounding and reverse causation in assessing cancer risk factors. Applied to BRCA studies, it strengthens evidence for causal links between mutations and disease.

Miki et al. (1994) used positional cloning to isolate BRCA1 from the 17q region linked to breast and ovarian cancer susceptibility. Mutations were verified in affected kindreds. This approach combined linkage analysis with genomic sequencing.